文献速递妇科

TMEM205信号异常表达促进卵巢癌铂类耐药:DAP化合物抗肿瘤潜力的启示

Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
PubMed 文献 · Gynecol Oncol · 2021-10-30

本研究探讨TMEM205在卵巢癌铂类耐药中的作用,发现耐药细胞系、血清及组织中TMEM205表达较敏感者高10-20倍,且与外泌体铂外排相关;TMEM205小分子抑制剂L-2663预处理可增加细胞内铂浓度、减少外排,与卡铂联用可降低耐药细胞存活及体内肿瘤生长。

要点

  • 耐药卵巢癌细胞系、血清及组织中TMEM205表达较敏感者高10-20倍。
  • 耐药细胞系卡铂处理后外泌体分泌较敏感细胞系显著增加5-10倍。
  • L-2663预处理可增加细胞内顺铂浓度并减少铂外排,与卡铂联用降低耐药细胞存活及肿瘤生长。

核心结论

  • TMEM205似通过外泌体途径外排铂类药物参与卵巢癌铂类耐药的发生。
  • 本研究提供临床前证据表明TMEM205可能作为铂类耐药的生物标志物及与铂类药物联用的治疗靶点。

研究设计与样本

  • 研究比较铂类敏感与耐药卵巢癌细胞系及患者血清/组织中TMEM205表达。
  • 采用电感耦合等离子体质谱(ICP-MS)评估TMEM205小分子抑制剂(L-2663/L-2797)预处理后的外泌体铂外排。
  • 在体外及体内模型中验证联合治疗的细胞毒性。

主要发现

  • 耐药卵巢癌细胞系、血清样本及组织中TMEM205表达较敏感者高10-20倍。
  • 原位邻近连接试验证实TMEM205与CD1B共定位,提示TMEM205可能通过外泌体途径介导铂类耐药。
  • 耐药细胞系卡铂处理后外泌体分泌较敏感细胞系显著增加5-10倍。
  • 卡铂前予L-2663预处理显著增加荧光标记顺铂的细胞内浓度并减少铂的外泌体外排。
  • 耐药细胞以L-2663联合卡铂处理较单用卡铂,体外细胞存活及体内肿瘤生长均降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: TMEM205 is a novel transmembrane protein associated with platinum resistance (PR) in epithelial ovarian carcinoma (OC), however, the specific mechanisms associated with this resistance remain to be elucidated. METHODS: TMEM205 expression was evaluated in platinum-sensitive (PS) versus platinum resistant (PR) ovarian cancer cell lines and patient serum/tissues. Exosomal efflux of platinum was evaluated with inductively coupled plasma mass spectrometry (ICP-MS) after pre-treatment with small molecule inhibitors (L-2663/L-2797) of TMEM205 prior to treatment with platinum. Cytotoxicity of combination treatment was confirmed in vitro and in an in vivo model. RESULTS: TMEM205 expression was 10-20 fold higher in PR compared to PS ovarian cancer cell lines, serum samples, and tissues. Co-localization with CD1B was confirmed by in-situ proximity ligation assay suggesting that TMEM205 may mediate PR via the exosomal pathway. Exosomal secretion was significantly increased 5-10 fold in PR cell lines after treatment with carboplatin compared to PS cell lines. Pre-treatment with L-2663 prior to carboplatin resulted in significantly increased intracellular concentration of fluorescently-labeled cisplatin and decreased exosomal efflux of platinum. Decreased cell survival and tumor growth in vitro and in vivo was observed when PR cells were treated with a combination of L-2663 with carboplatin compared to carboplatin alone. CONCLUSION: TMEM205 appears to be involved in the development of PR in ovarian cancer through the exosomal efflux of platinum agents. This study provides pre-clinical evidence that TMEM205 could serve as a possible biomarker for PR as well as a therapeutic target in combination with platinum agents.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Calo CA, Smith BQ, Dorayappan KDP, et al. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. Gynecol Oncol. 2021. PMID: 34756749. doi:10.1016/j.ygyno.2021.10.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。